Skip to main content
. 2019 Jan 14;191(2):E40–E46. doi: 10.1503/cmaj.180870

Table 1:

Health Canada–approved indications for immune checkpoint inhibitors in Canada (as of December 2018)*

Agent Advanced melanoma Advanced NSCLC Advanced RCC Advanced SCCHN Advanced bladder cancer Merkel cell cancer Hepato-cellular carcinoma Hodgkin lymphoma
CTLA-4 inhibitor
Ipilimumab All lines of treatment
PD-1 inhibitors
Pembrolizumab 1st-line
2nd-line		 1st-line: (≥ 50% PDL-1+)
2nd-line: (≥ 1% PDL-1+)		 2nd-line Post–autologous stem cell transplant
Nivolumab 1st-line
2nd-line		 2nd-line 2nd-line 2nd-line 2nd-line Post–autologous stem cell transplant
PDL-1 inhibitor
Atezolizumab 2nd-line 2nd-line
Avelumab 2nd-line
Durvalumab Post chemotherapy or radiation for stage III disease 2nd-line
Combination (CTLA-4 + PD-1)
Ipilimumab + nivolumab 1st-line 1st-line

Note: CTLA-4 = cytotoxic T-lymphocyte–associated protein 4, NSCLC = non–small cell lung cancer, PD-1 = programmed cell death 1, PDL-1 = programmed death-ligand 1, RCC = renal cell carcinoma, SCCHN = squamous cell carcinoma of head and neck.